Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors

Hana Kubová1, Zdeňka Bendová2,3, Simona Moravcová2,3

  • 1Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic.

Insights

Neonatal exposure to clonazepam alters GABAergic receptor expression and binding in developing rats, potentially leading to long-term behavioral deficits. These changes impact key brain regions involved in emotion and cognition.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Developmental Biology

Background:

  • Benzodiazepines (BZDs) are widely prescribed but can cause behavioral deficits in neonates.
  • Mechanisms of BZD-induced neurodevelopmental effects remain unclear.

Purpose of the Study:

  • To investigate the short- and long-term effects of neonatal clonazepam (CZP) exposure on GABAergic receptors in rats.
  • To determine the impact on GABAA and GABAB receptor subunit expression and binding.

Main Methods:

  • Neonatal rats (7-11 days old) received daily clonazepam (1 mg/kg).
  • RT-PCR and quantitative autoradiography assessed GABA receptor subunit expression and binding.
  • Analyses were conducted 48 hours, 1 week, and 2 months post-treatment.

Main Results:

  • Clonazepam altered GABAA receptor subunit expression (e.g., α2, δ, α4) in hippocampus and cortex.
  • GABAA receptor binding increased acutely, while benzodiazepine binding decreased long-term in emotion/cognition-related areas.
  • GABAB receptor binding varied by brain region and time post-treatment.

Conclusions:

  • Neonatal clonazepam exposure induces lasting changes in GABAergic receptor systems.
  • These alterations in synaptic function may underlie observed behavioral impairments.
  • Findings highlight critical developmental periods for BZD neurotoxicity.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.0K
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
639
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
527